PD-1/PD-L1 Inhibitor Binding Assay Kit
Immune checkpoint blockade is a groundbreaking approach in cancer immunotherapy that enhances the immune system’s ability to recognize and destroy cancer cells. The immune checkpoint PD- 1(CD279)/PD-L1 (CD274 or B7-H1) is an attractive target for cancer immunotherapy. The interaction of PD-1 with PD-L1 induces T cell apoptosis and allows cancer to evade the immune response by suppressing the adaptive immune system. Immunotherapy drugs work by blocking the interaction between PD-1 and PD-L1, and enhancing the anti-tumor immune response.
The PD-1/PD-L1 binding assay kit is a TR-FRET based assay, which is designed to detect the binding status between PD-1 and PD-L1. Tag6-PD-1 and Tag7-PD-L1 are included in this assay kit. Binding of Tag6-PD-1 to Tag7-PD-L1 brings the Terbium (Tb, HTRF donor) and the fluorophore d2 (HTRF acceptor) in a proximity distance, and activation of Tb results in fluorescence resonance energy transfer (FRET). Thus, the binding status can be quantitively measured by calculating the ratio of the emission fluorescence intensity of the acceptor (665 nm) and donor (620 nm). Interference of the PD-1/PD-L1 binding will reduce the HTRF signal.
